In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) closed at $1.4 up 1.45% from its previous closing price of $1.38. In other words, the price has increased by $1.45 from its previous closing price. On the day, 0.63 million shares were traded. ZNTL stock price reached its highest trading level at $1.41 during the session, while it also had its lowest trading level at $1.36.
Ratios:
For a deeper understanding of Zentalis Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.76 and its Current Ratio is at 7.76. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.15.
On June 20, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $28 to $5.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 30 ’25 when Myers Scott Dunseth bought 21,000 shares for $1.40 per share. The transaction valued at 29,373 led to the insider holds 281,192 shares of the business.
Bruns Ingmar bought 20,000 shares of ZNTL for $45,656 on Feb 06 ’25. The Chief Medical Officer now owns 36,629 shares after completing the transaction at $2.28 per share. On Feb 11 ’25, another insider, Cam Gallagher, who serves as the Former Director of the company, bought 687 shares for $2.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZNTL now has a Market Capitalization of 101151088 and an Enterprise Value of -139088912. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.77 while its Price-to-Book (P/B) ratio in mrq is 0.40. Its current Enterprise Value per Revenue stands at -5.177 whereas that against EBITDA is 0.917.
Stock Price History:
The Beta on a monthly basis for ZNTL is 1.75, which has changed by -0.6057143 over the last 52 weeks, in comparison to a change of 0.12469888 over the same period for the S&P500. Over the past 52 weeks, ZNTL has reached a high of $4.00, while it has fallen to a 52-week low of $1.01. The 50-Day Moving Average of the stock is -5.74%, while the 200-Day Moving Average is calculated to be -6.64%.
Shares Statistics:
For the past three months, ZNTL has traded an average of 673.27K shares per day and 444260 over the past ten days. A total of 72.25M shares are outstanding, with a floating share count of 59.48M. Insiders hold about 17.68% of the company’s shares, while institutions hold 75.44% stake in the company. Shares short for ZNTL as of 1763078400 were 5084883 with a Short Ratio of 7.55, compared to 1760486400 on 4936914. Therefore, it implies a Short% of Shares Outstanding of 5084883 and a Short% of Float of 8.7799996.
Earnings Estimates
The stock of Zentalis Pharmaceuticals Inc (ZNTL) is currently drawing attention from 7.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.38 and low estimates of -$0.55.
Analysts are recommending an EPS of between -$1.37 and -$1.95 for the fiscal current year, implying an average EPS of -$1.76. EPS for the following year is -$1.6, with 7.0 analysts recommending between -$1.05 and -$2.27.
